Edgewise Therapeutics Inc. Common Stock vs H World Group Limited American Depositary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while H World Group Limited American Depositary Shares trades at $44.25 (market cap $14.16B). The key difference: H World Group Limited American Depositary Shares is far larger — about 3.6× Edgewise Therapeutics Inc. Common Stock's market cap, and H World Group Limited American Depositary Shares pays a 4.91% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and H World Group Limited American Depositary Shares for 6 Days on average.
| EWTX | HTHT | |
|---|---|---|
Market Cap | $3.94B | $14.16B |
Volume | 810,104 | 1,525,108 |
Sector | Health | Consumer Cyclical |
52-Week High | $48.35 | $56.06 |
52-Week Low | $14.89 | $36.99 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $3.48B | $16.95B |
Dividend Yield | — | 4.91% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →